Using Targeted Inhibitors in the Management of Chronic Lymphocytic Leukemia: Are We There Yet?
November 15th 2016Several critical issues need to be addressed during the next several years if we are to reach the true potential of new agents like ibrutinib, idelalisib, venetoclax, ofatumumab, and obinutuzumab-which conceivably could ultimately cure CLL.